The choice of controlled rate freezer vs freezing container decides whether a lab actively controls how its cells cool, or simply sets the boundary conditions and accepts the outcome. A passive freezing container is an insulated device that, placed in a –80 °C freezer, cools cryovials at approximately –1 °C/min. A controlled rate freezer, often called a programmable freezer, regulates temperature to a defined profile and records every run.
On paper, both deliver the same rate. The difference shows up where it counts: at the moment ice forms, with sensitive cells, with cryobags — and when an auditor asks how a batch was frozen.
The honest answer first: not every lab needs a controlled rate freezer.
A passive freezing container slows the flow of heat out of the samples through a defined thermal resistance. Cryovials sit either in an isopropanol-filled container or in an alcohol-free passive cooling device made of insulating material around a thermally conductive core. In a –80 °C freezer they cool at approximately –1 °C/min, with no power, no program and no operator input.
Its strengths are genuine. It is inexpensive, needs no training and uses the –80 °C freezer the lab already has. For robust cell lines, it has been an established method for decades.
One point explains its limits: the rate is not a setting but an outcome of temperature difference, insulation and thermal mass. Nor is the curve linear — it flattens as the sample approaches freezer temperature.
A passive container falls short as soon as reproducibility, sensitive cells, larger volumes or documented evidence are required. The weaknesses lie in the principle, not in the handling.
The real rate depends on freezer temperature, position in the freezer, how many containers go in at once, door openings and, for isopropanol designs, the condition of the alcohol. Even within one run, vials can cool differently depending on where they sit. Two runs to the same protocol are not necessarily two identical runs.
A cooling sample first drops below its freezing point without freezing: it is supercooled. When ice nucleation finally occurs, the latent heat of fusion is released almost instantly — around 334 joules per gram of water frozen, in principle enough to warm the same mass of liquid water by roughly 80 kelvin. Sample temperature jumps several degrees.
In a passive container, that heat can only escape through the same insulation that is deliberately slowing the cooling. The sample lingers near its freezing point and passes through the critical range at something other than the nominal rate. Because nucleation is random, every vial ends up with its own thermal history.
The deeper the supercooling, the more abrupt the transition — and, for sensitive cells, the greater the risk of intracellular ice. Robust cell lines usually cope. Haematopoietic stem cells, iPSCs and T-cell products are considered far less forgiving.
A passive container leaves no record, so nothing shows that a run actually followed –1 °C/min. It is also designed for cryovials; cryobags and larger volumes cannot be frozen in it reproducibly.
A controlled rate freezer actively regulates chamber temperature to a programmed profile, absorbs the released heat of crystallisation with a targeted compensation step and records every run. Cooling becomes a defined, repeatable process step.
Equally honest: a controlled rate freezer controls the freezing step, not the whole process. DMSO exposure, cell density and thawing still decide the outcome, and each freezing profile has to be developed and validated for its cell type.
The BIOFREEZE® BV45 is the standard controlled rate freezer for general laboratory and biobanking applications. The BIOFREEZE® SMARTLINE adds extended automation for pharmaceutical, GMP and high-throughput settings, for example when laying down large vial series for a cell bank.
The decision turns less on budget than on three questions: how replaceable are the cells, how sensitive are they to cooling, and does the freezing process have to be proven? If cell freezing in your lab clears all three without concern, a passive container will serve you well.
Many facilities run both: passive containers for routine research stocks, a programmable freezer for cell banks and clinical material. That is not inconsistency. It is placing control where the risk sits.
Economically, the deciding factor is not purchase price but the value of what is being frozen — and the cost of a failed run. A passive container is far cheaper to buy, but that advantage shrinks as the value of the samples rises.
An illustrative example, deliberately without figures: in basic research, a failed run with a standard cell line costs a few days of culture work. In cell therapy, the same failure can hit a patient-specific batch that cannot be manufactured again.
That is why risk-adjusted total cost of ownership is the better lens: purchase, operation, qualification and maintenance on one side; the likelihood and consequences of a lost run on the other. Where a single lost batch would outweigh the extra cost of a controlled rate freezer, the passive container is the more expensive option. Where it would not, the container is the sensible one.
Controlled freezing does not end with the program. Samples must go into long-term liquid nitrogen storage without intermediate warming, because recrystallisation continues above the glass transition temperature of roughly –130 °C.
For biobanking and pharmaceutical applications, Consarctic® supplies the BSD+ series — stainless steel cryogenic tanks for long-term storage, holding up to 100,000 cryovials — and the BSF+ series for vials and cryobags; according to its datasheet, the BSF420+ holds, for example, 380 cryobags of 500 ml. Samples are kept in the vapour phase, and the eccentric tank opening can cut LN₂ consumption by up to 30 %. The Consarctic® Monitoring System tracks temperature and fill level continuously.
Commissioning includes installation and operational qualification (IQ/OQ) of the freezer by certified Consarctic GmbH technicians, the basis on which users validate their own freezing profile. Lifecycle & Compliance Care covers maintenance and software updates, and the 24/7 emergency service is available 365 days a year.
Under GMP, the freezing step must be validated and every batch documented; biobanks working to ISO 20387 need validated or verified methods for processing and preservation. Consarctic GmbH is certified to EN ISO 13485:2016 and ISO 9001:2015, manufactures its systems to GMP-compliant standards and serves customers in more than 30 countries, among them Roche, Bayer, the Max Planck Gesellschaft, Swiss Stem Cells Biotech and the Finnish Red Cross.
For robust, easily replaced cell lines in routine research, often yes. In a –80 °C freezer it delivers approximately –1 °C/min and is inexpensive and simple to use. It does not, however, control the rate, compensate for latent heat of fusion or record the cooling curve.
Not reproducibly. Passive cooling devices are designed for cryovials, not for the geometry and volume of cryobags. Bags of cell therapy or stem cell material are generally frozen in a controlled rate freezer.
GMP does not mandate a specific instrument; it requires a validated, controlled and documented process. That evidence is hard to produce with a passive container, which neither sets the rate nor records it. In GMP cell therapy manufacturing, a controlled rate freezer with recorded runs is therefore the usual route.
Facilities where a failed run is costly, unrepeatable or subject to regulatory scrutiny: GMP cell therapy manufacturing, pharmaceutical cell banks, stem cell banks and biobanks working to ISO 20387, and labs freezing cryobags or sensitive cells. That is where the Consarctic® BIOFREEZE® BV45 and BIOFREEZE® SMARTLINE earn their place, with TC-Aktiv compensation of crystallisation heat, audit-trail-compatible recording and runs that do not depend on the operator. Labs freezing small numbers of robust cell lines with no documentation requirement are often better served by a basic passive freezing container.
A passive freezing container is a good tool for what it was designed to do: robust cells, small numbers, no burden of proof. Once cells become irreplaceable, sensitive or regulated, cooling becomes a process step that has to be controlled, compensated and evidenced.
Weighing up whether your lab needs a controlled rate freezer? Consarctic GmbH will advise on the right solution — including when the simpler one is enough — and supplies, qualifies and supports BIOFREEZE® and the cryogenic storage behind it as one accountable partner, from first conversation to a running, GMP-validated facility. Get in touch.